3 Year Follow up on ANO5 Patients

Neuromuscular Diseases Clinical Trial

Official title: 3 Year Follow up on Patients With Pathogenic Anoctamin 5 Variants

Status Active, not recruiting

Clinical Trial Summary

The aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to:

1. investigate possible progression of disease over time

2. investigate good and reliable outcome measures

Clinical Trial Description

Muscles of patients with pathogenic variants in the anoctamin 5 gene will over time be infiltrated with fat. This is especially visible on MRI and can be seen even before any symptoms appear. MRI is thus used increasingly to investigate muscle affection in neuromuscular disorders. Together with functional measurements it is possible to describe how patients are affected clinically and subclinically. There are still many things that need covering - rate of progression is undertermined and good outcome measures are still needed for future clinical trials.

Muscles of the whole body in patients with neuromuscular disorders will be investigated 3 times through a 3 year follow-up study.

The aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to:

1. investigate possible progression of disease over time

2. investigate good and reliable outcome measures ;

Related Conditions & MeSH terms

• Limb Girdle Muscular Dystrophy
• Muscular Dystrophies
• Neuromuscular Diseases

• NCT number: NCT05206617
• Study type: Observational
• Source: Rigshospitalet, Denmark
• Status: Active, not recruiting
• Start date: January 1, 2018
• Completion date: November 1, 2025